356783-29-4

Basic information

• Product Name: Pyrazinecarboxamide, 3,6-difluoro- (9CI)
• Synonyms: Pyrazinecarboxamide, 3,6-difluoro- (9CI);3,6-difluoropyrazine-2-carboxaMide
• CAS NO: 356783-29-4
• Molecular Formula: C₅H₃F₂N₃O
• Molecular Weight: 159.0936264
• Product Categories: AMIDE;HALIDE
• Mol File: 356783-29-4.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Pyrazinecarboxamide, 3,6-difluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrazinecarboxamide, 3,6-difluoro- (9CI)(356783-29-4)
• EPA Substance Registry System: Pyrazinecarboxamide, 3,6-difluoro- (9CI)(356783-29-4)

Safety Data

• Hazardous Substances Data: 356783-29-4(Hazardous Substances Data)

Usage

Description

Pyrazinecarboxamide, 3,6-difluoro(9CI) is a chemical compound belonging to the pyrazine family, characterized by the presence of two fluorine atoms at the 3rd and 6th positions. It is a derivative of pyrazinecarboxamide, which is a heterocyclic compound with potential applications in various fields due to its unique structural properties.

Uses

Used in Pharmaceutical Industry:
Pyrazinecarboxamide, 3,6-difluoro(9CI) is used as a building block for the synthesis of Des-(3-Oxo-3,4-dihydrogen) 3,6-Difluoro Favipiravir, which is related to Favipiravir (F103350). Favipiravir is an antiviral drug used for the treatment of advanced Ebola virus infection in a small animal model. It has demonstrated the ability to suppress the replication of Zaire Ebola virus and prevent a lethal outcome in 100% of the animals. Based on these studies, Favipiravir can be considered a candidate for the treatment of Ebola hemorrhagic fever.

Upstream product

• 356783-28-3 3,6-difluoropyrazine-2-carbonitrile 
• 19847-12-2 2-pyrazine carbonitrile 
• 18960-19-5 1,4-dioxopyrazinamide 
• 356783-16-9 3,6-dichloropyrazine-2-carbonitrile 
• 5424-01-1 3-aminopyrazinoic acid 
• 16298-03-6 Methyl 3-amino-2-pyrazinecarboxylate 
• 6966-01-4 methyl 3-amino-6-bromopyrazine-2-carboxylate 
• 21874-61-3 3-hydroxy-6-bromopyrazine-2-carboxylic acid methyl ester 
• 1301613-77-3 3,6-dibromo-2-pyrazinamide 
• 17231-50-4 6-chloro-3-aminopyrazine-2-carbonitrile 
• 356783-26-1 methyl 3,6-difluoropyrazine-2-carboxylate 

Downstream Products

• 259793-96-9 favipiravir 

Relevant articles and documents

METHODS FOR PREPARING FAVIPIRAVIR

The present invention provides methods for preparing Favipiravir (6-fluoro-3-hydroxypyrazine-2-carboxamide).

Preparation method of favipiravir

The invention relates to a preparation method of favipiravir. The preparation method comprises the following steps: dissolving 6-bromine-3-hydroxypyrazine-2-formamide in a first solvent, adding a first fluorinating agent, and carrying out a stirring reaction so as to prepare 6-bromine-3-fluoropyrazine-2-formamide; dissolving the 6-bromo-3-fluoropyrazine-2-formamide, a second fluorinating agent anda catalyst in a second solvent, and carrying out a heating reaction to prepare 6-fluoro-3-fluoropyrazine-2-formamide; and carrying out hydroxyl substitution on the 6-fluoro-3-fluoropyrazine-2-formamide to prepare the favipiravir. The invention further discloses a preparation method of the favipiravir. The preparation method of favipiravir has the advantages of simple and safe reaction operation,less three wastes, green and environment-friendly synthetic route and environmental friendliness; the favipiravir has the advantages of higher yield, stability and low production cost, and is suitablefor industrial production.

Favipiravir intermediate and synthetic method for favipiravir

The invention relates to a favipiravir intermediate and a synthetic method for favipiravir, and specifically discloses a method for synthesizing 3,6-difluoro-2-cyanopyrazine with a formula 4 as shownin the specification. The method comprises the following steps: a) allowing a compound with a formula 1 as shown in the specification to react with a chlorinated reagent or a brominated reagent so asto obtain a compound with a formula 2 as shown in the specification; b) allowing the compound with the formula 2 as shown in the specification to react with phosphorus oxychloride in the presence of organic base so as to obtain a compound with a formula 3 as shown in the specification; and c) allowing the compound with the formula 3 as shown in the specification to react with a fluorinated reagentso as to obtain the compound with the formula 4 as shown in the specification. The invention also relates to a method for synthesizing the favipiravir by using the above-mentioned method.